Orthobiologics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Orthobiologics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The orthobiologics market is expected to grow at a significant CAGR of 4.12% during the study period, 2022-2027.

The COVID-19 outbreak is an unprecedented health concern and has significantly impacted the orthobiologics market globally. According to a 2021 update by the National Safety Council (NSC) in America, the Consumer Product Safety Commission (CPSC) reported that during the first seven months of the COVID-19 pandemic, visits to emergency departments for consumer product-related injuries decreased by 24%. The highest decrease in injuries was sports-related injuries associated with track and field. Hockey, soccer, baseball, football, and basketball witnessed a more than 60% reduction from March through September 2020. As per the CPSC, these large decreases were due to the suspension of school and youth sports leagues in the spring and summer months of 2020 in response to the pandemic. Furthermore, due to the reallocation of resources to COVID departments, non-emergency services related to osteoarthritis were suspended, impacting the demand for orhobiologics. Thus, the COVID-19 imposed lockdown impacted the orthobiologics market significantly.

The major factors driving the growth of the orthobiologics market are increased incidence of sports injury, road accidents, osteoarthritis, and increasing adoption of minimally invasive surgeries. As per the 2020 statistics by the United Kingdom National Health Service, tennis elbow is a common condition affecting about 1-3% of the population, indicating about four to seven cases per 1000 every year. The high incidences of sports injuries boost the demand for orthobiologics for effective treatment, thus fueling the market.

The global increase in the number of geriatrics and obese people is likely to lead to consequences, like greater incidences of osteoarthritis. Consequently, the geriatric population and population with obesity are at higher risk of musculoskeletal disorders. According to the 2021 statistics by the World Health Organization (WHO), an estimated 305 million people globally suffer from musculoskeletal injuries, while 222 million people suffer from neck pain. Therefore, with the increase in musculoskeletal injuries, the demand for orthobiologics is expected to increase, driving the market growth.

Moreover, launching new products and strategic initiatives adopted by key market players is expected to boost the studied market growth. For instance, in April 2021, Ventris Medical launched Allocell AF, a next-generation osteoinductive fiber allograft. It enhances intra-operative handling and increases biologic responsiveness at the defect site.

Thus, due to the factors mentioned above, the studied market is expected to grow significantly during the study period. However, the high cost of biologic-based treatments and preference for other alternatives is expected to hinder the market growth.

Key Market TrendsThe Osteoarthritis and Degenerative Arthritis Segment is Expected to Experience the Fastest Growth in the Market

Osteoarthritis is a very common condition that may affect any joint in the body. It is most likely to affect the joints that bear most of our weight, such as the knees and feet. Furthermore, joints used in everyday life, such as the hand joints, are commonly affected. The factors such as the increasing burden of osteoarthritis, growing geriatric population, increasing product launches, and rise in strategic initiatives by key market players are expected to further drive the market growth.

According to a report, "OA Prevalence & Burden," published in September 2019, osteoarthritis is the most common form of arthritis, affecting almost 32.5 million United States adults. 43% of people with OA are 65 or older, and 88% of people with OA are 45 or older. 62% of individuals with OA are women.

Additionally, the product launches will expand the product offering in the studied segment with more efficient products, thus driving the segment. For instance, in April 2021, Organicell Regenerative Medicine, Inc. received the approval of the US Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for Zofin in treating knee osteoarthritis. Zofin is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs,

Moreover, strategic initiatives such as mergers and acquisitions and partnerships by key market players may expand their product portfolio, and their geographical footprint may help contribute to the market growth. For instance, in April 2022, Juniper Biologics acquired cell-mediated gene therapy for the treatment of knee osteoarthritis from Kolon Life Science for USD 600 million. Under the agreement, Juniper Biologics gained the licensing rights to develop and commercialize TG-C LD (TissueGene-C low dose) for the treatment of knee osteoarthritis.

Thus, due to the factors mentioned above, the studied segment is expected to contribute to the significant growth of the market.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

The primary driving factors for the growth of the North American Orth biologics market are rising incidences of sports injuries and road accidents, rising incidence of osteoarthritis, growing geriatric and obese population, and increasing prevalence of minimally surgical procedures. In addition, rising product launches and strategic initiatives by key market players may also contribute to market growth.

The United States within North America is expected to hold a significant share of the studied market during the study period. For instance, as per the research study titled “Sports participation and injury rates in high school students: A Canadian survey of 2029 adolescents” published in July 2021, 889 participants out of 1,971 reported at least one injury during the past year with an incidence rate of about 45.10 per 100 students per year and concluded that incidence rate of the injuries due to sports and recreation activities was high in high school students with 29% of adolescents reporting at least one medical attention injury within the past year.

Additionally, growing product launches in the region contribute to market growth. For instance, in March 2020, Pfizer Inc. and Eli Lilly and Company announced that the US Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC), which is being evaluated for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics. In February 2021, Signature Biologics LLC announced that the US Food and Drug Administration (FDA) had approved an IND Application to proceed with the study of Signature Cord Prime in patients with symptomatic osteoarthritis (OA) of the knee. Signature Cord Prime is a cryopreserved, human umbilical cord tissue allograft for managing symptomatic knee osteoarthritis.

Thus, due to the factors mentioned above, the studied market is expected to witness significant growth during the study period.

Competitive Landscape

The orthobiologics market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of diseases, few other smaller players are expected to enter the market in the future. Some of the market's major players are Sanofi, Stryker, Zimmer Biomet, Seaspine Holdings Corporation, and Medtronic, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.